You are here

Article Text

Article menu

Download PDFPDF

At a glance
At a glance
Free
  1. Harminder S Dua,
  2. Arun D Singh, Editors-in-Chief

https://doi.org/10.1136/bjo.2010.185751

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Topical interferon alpha 2b for OSSN

    Galor et al compared the effectiveness and side-effect profile of two doses of interferon α2b (IFNa2b) eye-drops (1 million IU/ml vs 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). In a retrospective case series of 33 eyes with conjunctival intraepithelial neoplasia (CIN), 21 eyes were treated with 1 million IU/ml of topical IFN-a2b; 12 eyes with CIN were treated with 3 million IU/ml. Topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group (p=0.41). Topical therapy was well tolerated. The mean time to tumour resolution was about 12 weeks. After a median follow-up of 24 months, three recurrences were observed. Two eyes with squamous cell carcinoma did not respond to interferon therapy. The authors conclude that, there were no significant differences in the effectiveness between the two dose formulations of IFN-a2b. See page 551

    Phacoemulsification skills training and assessment

    Spiteri et al review …

    View Full Text

    Linked Articles